초록 ▼

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activi

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

대표청구항 ▼

1. An isolated antibody or antigen-binding fragment thereof, comprising: a) a heavy chain variable region sequence comprising the three CDR sequences of SEQ ID NOs: 7-9; orb) a light chain variable region sequence comprising the three CDR sequences of SEQ ID NOs:10-12, wherein the isolated antibody,

1. An isolated antibody or antigen-binding fragment thereof, comprising: a) a heavy chain variable region sequence comprising the three CDR sequences of SEQ ID NOs: 7-9; orb) a light chain variable region sequence comprising the three CDR sequences of SEQ ID NOs:10-12, wherein the isolated antibody, or antigen-binding fragment thereof, binds to a PD-1 protein having the amino acid sequence of SEQ ID NO: 2, and the isolated antibody, or antigen-binding fragment thereof, is chimeric, humanized, composite, or human. 2. The isolated antibody or antigen-binding fragment of claim 1, comprising: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 25-29, or a sequence with at least about 95% homology to a heavy chain sequence selected from the group consisting of SEQ ID NOs: 25-29; orb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 30-33, or a sequence with at least about 95% homology to a light chain sequence selected from the group consisting of SEQ ID NOs: 30-33. 3. The isolated antibody or antigen-binding fragment of claim 2, comprising: a) a heavy chain variable region sequence comprising SEQ ID NO: 27 or 28, or a sequence with at least about 95% homology to a heavy chain sequence comprising SEQ ID NO: 27 or 28; andb) a light chain variable region sequence comprising SEQ ID NO: 32 or 33, or a sequence with at least about 95% homology to a light chain sequence comprising SEQ ID NO: 32 or 33. 4. The isolated antibody or antigen-binding fragment of claim 1, wherein the isolated antibody or antigen-binding fragment inhibits the binding of an antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO:76 and a light chain variable region comprising the sequence of SEQ ID NO:77 to Fc-PD-1. 5. The isolated antibody or antigen-binding fragment of claim 1, wherein the isolated antibody or antigen-binding fragment inhibits a PD-1-mediated signal. 6. An isolated nucleic acid encoding a polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs: 25-33, or a sequence with at least about 95% homology to a sequence selected from the group consisting of SEQ ID NOs: 25-33. 7. An isolated nucleic acid encoding the antibody or antigen-binding fragment of claim 1. 8. A vector comprising the isolated nucleic acid of claim 7. 9. An isolated host cell comprising the nucleic acid of claim 7. 10. The host cell of claim 9 that produces the antibody or antigen-binding fragment encoded by the nucleic acid. 11. A pharmaceutical composition, comprising the isolated antibody or antigen-binding fragment of claim 1 and a pharmaceutically-acceptable carrier. 12. A method of reactivating exhausted T cells, comprising contacting a population of T cells, wherein at least some T cells express PD-1, with an effective amount of a composition comprising an antibody, or an antigen-binding fragment thereof, of claim 1. 13. The method of claim 12, wherein the step of contacting is performed in vitro, ex vivo, or in vivo. 14. A method of treating a subject suffering from cancer, comprising administering to the subject a composition comprising an effective amount of an isolated antibody, or an antigen-binding fragment thereof, of claim 1. 15. The method of claim 14, wherein the cancer is selected from the group consisting of a solid tumor, a hematologic cancer, bladder cancer, brain cancer, breast cancer, colon cancer, gastric cancer, glioma, head cancer, leukemia, liver cancer, lung cancer, lymphoma, myeloma, neck cancer, ovarian cancer, melanoma, pancreatic cancer, renal cancer, salivary cancer, stomach cancer, thymic epithelial cancer, and thyroid cancer. 16. A method of producing the antibody or antigen-binding fragment of claim 1, comprising culturing a cell that produces the antibody or antigen-binding fragment, and recovering the antibody or antigen-binding fragment from the cell culture. 17. The isolated antibody or antigen-binding fragment of claim 1, comprising: a) a heavy chain variable region sequence comprising the three CDR sequences of SEQ ID NOs: 7-9; andb) a light chain variable region sequence comprising the three CDR sequences of SEQ ID NOs:10-12. 18. The isolated antibody or antigen-binding fragment of claim 17, comprising: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 25-29, or a sequence with at least about 95% homology to a heavy chain sequence selected from the group consisting of SEQ ID NOs: 25-29; andb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 30-33, or a sequence with at least about 95% homology to a light chain sequence selected from the group consisting of SEQ ID NOs: 30-33. 19. The isolated antibody or antigen-binding fragment of claim 2, comprising: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 25-29; orb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 30-33. 20. The isolated antibody or antigen-binding fragment of claim 19, comprising: a) a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 25-29; andb) a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 30-33. 21. The isolated antibody or antigen-binding fragment of claim 20, comprising: a) a heavy chain variable region sequence comprising SEQ ID NO: 27 or 28; andb) a light chain variable region sequence comprising SEQ ID NO: 32 or 33.